Telatinib is a selective tyrosine kinase inhibitor primarily investigated for its potential in cancer treatment, especially in gastrointestinal tumors. It targets receptors involved in angiogenesis and tumor growth, such as VEGFR-2, EGFR, and PDGFR. Due to its specificity, it has been studied in clinical trials for advanced colorectal and gastric cancers. Its application focuses on inhibiting tumor blood vessel formation and blocking signaling pathways that promote cancer cell proliferation. Research also explores its use in combination with other chemotherapeutic agents to enhance efficacy and overcome resistance.